Literature DB >> 28398281

An interim analysis of the ZUMA-1 study of KTE-C19 in refractory, aggressive non-Hodgkin lymphoma.

Sattva S Neelapu1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28398281

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  11 in total

Review 1.  Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma.

Authors:  Armin Ghobadi
Journal:  Curr Res Transl Med       Date:  2018-04-11       Impact factor: 4.513

Review 2.  CAR T Cell Therapy for Hematological Malignancies.

Authors:  Xin Yang; Gao-Xiang Wang; Jian-Feng Zhou
Journal:  Curr Med Sci       Date:  2019-12-16

Review 3.  Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.

Authors:  Moritz Ernst; Annika Oeser; Burcu Besiroglu; Julia Caro-Valenzuela; Mohamed Abd El Aziz; Ina Monsef; Peter Borchmann; Lise J Estcourt; Nicole Skoetz; Marius Goldkuhle
Journal:  Cochrane Database Syst Rev       Date:  2021-09-13

4.  Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma: a single-center study.

Authors:  Chen Huang; Lili Wu; Ruixia Liu; Weijing Li; Zheng Li; Jianqiang Li; Lihong Liu; Baoen Shan
Journal:  Ann Transl Med       Date:  2020-09

Review 5.  Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.

Authors:  Samaresh Sau; Hashem O Alsaab; Ketki Bhise; Rami Alzhrani; Ghazal Nabil; Arun K Iyer
Journal:  J Control Release       Date:  2018-01-31       Impact factor: 9.776

6.  Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists.

Authors:  Christopher T Petersen; Mojibade Hassan; Anna B Morris; Jasmin Jeffery; Kunhee Lee; Neera Jagirdar; Ashley D Staton; Sunil S Raikar; Harold T Spencer; Todd Sulchek; Christopher R Flowers; Edmund K Waller
Journal:  Blood Adv       Date:  2018-02-13

Review 7.  Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies.

Authors:  Weiqi Yan; Zhuojun Liu; Jia Liu; Yuanshi Xia; Kai Hu; Jian Yu
Journal:  Biomed Res Int       Date:  2020-10-01       Impact factor: 3.411

Review 8.  A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.

Authors:  Faroogh Marofi; Heshu Sulaiman Rahman; Muhammad Harun Achmad; Klunko Nataliya Sergeevna; Wanich Suksatan; Walid Kamal Abdelbasset; Maria Vladimirovna Mikhailova; Navid Shomali; Mahboubeh Yazdanifar; Ali Hassanzadeh; Majid Ahmadi; Roza Motavalli; Yashwant Pathak; Sepideh Izadi; Mostafa Jarahian
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

Review 9.  Management of the Critically Ill Adult Chimeric Antigen Receptor-T Cell Therapy Patient: A Critical Care Perspective.

Authors:  Cristina Gutierrez; Colleen McEvoy; Elena Mead; R Scott Stephens; Laveena Munshi; Michael E Detsky; Stephen M Pastores; Joseph L Nates
Journal:  Crit Care Med       Date:  2018-09       Impact factor: 9.296

Review 10.  Defining success with cellular therapeutics: the current landscape for clinical end point and toxicity analysis.

Authors:  Leslie S Kean
Journal:  Blood       Date:  2018-05-04       Impact factor: 25.476
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.